<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04928300</url>
  </required_header>
  <id_info>
    <org_study_id>17300614</org_study_id>
    <nct_id>NCT04928300</nct_id>
  </id_info>
  <brief_title>Low Dose Dexmedetomidine Versus Ketamine in Multiple Fracture Ribs</brief_title>
  <official_title>Diaphragmatic Function, Pain Quality &amp; Anti-inflammatory Properties: A Low Dose Dexmedetomidine Versus Ketamine in Patients With Multiple Fracture Ribs Needing Conservative Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assiut University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In our study, we assess the diaphragmatic function, pain quality and anti-inflammatory&#xD;
      properties between low dose infusion of dexmedetomidine and ketamine in patients with&#xD;
      multiple fracture ribs on conservative treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A written informed consent from patients or thier legal guardians, Patients will be assigned&#xD;
      randomly to three groups (30 subjects each) with traumatic multiple fracture ribs 3 ribs or&#xD;
      more. After thoracic epidural is inserted, the drug study intervention will be started and&#xD;
      run for 5 days during ICU admission. In (Group D) low dose dexmedetomidine infusion 0.2&#xD;
      µ/kg/hour IV for 5 days. In (Group K) low dose ketamine infusion 2.5 µ/kg/min for 5 days. In&#xD;
      (Group C) the same dose and duration of normal saline will be given.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 12, 2021</start_date>
  <completion_date type="Anticipated">December 25, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 20, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ultrasonographic diaphragm function</measure>
    <time_frame>5 days</time_frame>
    <description>Diaphragmatic excursion and thickness will be assessed by ultasound for 5 days with diaphragmatic dysfunction (DD) is diagnosed if diaphragmatic excursion is &lt;10 mm and diaphragmatic thickness is &lt;2 mm. .</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Visual analogue scale for pain</measure>
    <time_frame>48 hours</time_frame>
    <description>Severity of pain will be assessed and scored by 10-point visual analogue scale (VAS). The patients will be instructed on how to use VAS for the assessment of the degree of pain (with 0 representing no pain and 10 cm representing the worst imaginable pain). According to the degree pain given by the patient, classification of pain severity will be done as follows: no pain = 0, mild pain &lt;3, moderate pain 4-6 and severe pain &gt;7. VAS will be recorded at zero time before drug intervention, 4 h, 6 h, 12 h, 24 h and 48 h after the start of the treatment in all groups by the anesthesia resident not involved in any other part of the study.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Neutrophil/lymphocyte ratio (NLR)</measure>
    <time_frame>3 days</time_frame>
    <description>From complete blood picture, neutrophil/lymphocyte ratio is measured to assess anti-inflammatory properties of the study drugs daily for 3 days.</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Rib Fractures</condition>
  <arm_group>
    <arm_group_label>Group D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dexmedetomidine infusion IV for 5 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group K</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ketamine infusion 2.5 µ/kg/min for 5 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group C</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The same dose and duration of normal saline will be given.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexmedetomidine</intervention_name>
    <description>low dose dexmedetomidine infusion 0.2 µ/kg/hour IV for 5 days.</description>
    <arm_group_label>Group D</arm_group_label>
    <other_name>Precedex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketamine</intervention_name>
    <description>low dose ketamine infusion 2.5 µ/kg/min for 5 days.</description>
    <arm_group_label>Group K</arm_group_label>
    <other_name>ketalar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>0.9% saline</intervention_name>
    <description>the same dose and duration of normal saline will be given for 5 days.</description>
    <arm_group_label>Group C</arm_group_label>
    <other_name>Normal saline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adults (age 18-65 years) of American Society of Anaesthesiologists (ASA) physical&#xD;
             status I-II&#xD;
&#xD;
          -  Traumatic multiple fracture ribs 3 ribs or more, who will be subjected to thorough&#xD;
             assessments including chest 3D-CT&#xD;
&#xD;
          -  Undergoing conservative treatment (chest strappings)&#xD;
&#xD;
          -  Intractable pain with visual analogue scale (VAS) over 6 after traditional therapies&#xD;
&#xD;
          -  Glasgow Coma Scale (GCS) ≥ 13.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Multiple traumas to body parts other than chest with an abbreviated injury scale over&#xD;
             3&#xD;
&#xD;
          -  Serious head trauma with a Glasgow coma scale lower than 13&#xD;
&#xD;
          -  Mechanically ventilated patients&#xD;
&#xD;
          -  Massive hemothorax&#xD;
&#xD;
          -  Injury to the trachea or bronchus with requirement for immediate surgery&#xD;
&#xD;
          -  Dementia&#xD;
&#xD;
          -  Use of corticosteroids during ICU stay&#xD;
&#xD;
          -  Sepsis&#xD;
&#xD;
          -  Continued use of neuromuscular blocking agents and aminoglycosides antibiotic use as&#xD;
             they are known risk factors for ICU-acquired weakness and any known hypersensitivity&#xD;
&#xD;
          -  Contraindication to the study drugs.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Omar Soliman, MD</last_name>
    <role>Study Director</role>
    <affiliation>Assiut University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Omar Soliman, MD</last_name>
    <phone>01101266040</phone>
    <email>omarmakram347@yahoo.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Assiut university hospital</name>
      <address>
        <city>Assiut</city>
        <state>Assuit</state>
        <zip>Assuit universi</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Omar Soliman</last_name>
      <phone>01101266040</phone>
      <email>omarmakram347@yahoo.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <results_reference>
    <citation>Bossolasco M, Bernardi E, Fenoglio LM. Continuous serratus plane block in a patient with multiple rib fractures. J Clin Anesth. 2017 May;38:85-86. doi: 10.1016/j.jclinane.2016.12.015. Epub 2017 Jan 30.</citation>
    <PMID>28372691</PMID>
  </results_reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>June 10, 2021</study_first_submitted>
  <study_first_submitted_qc>June 10, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 16, 2021</study_first_posted>
  <last_update_submitted>October 11, 2021</last_update_submitted>
  <last_update_submitted_qc>October 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>Omar Makram Soliman</investigator_full_name>
    <investigator_title>Lecturer of anesthesia and ICU</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fractures, Bone</mesh_term>
    <mesh_term>Rib Fractures</mesh_term>
    <mesh_term>Fractures, Multiple</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexmedetomidine</mesh_term>
    <mesh_term>Ketamine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

